Market Overview:
The global glucosylceramidase market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of genetic disorders, Gaucher disease, and Parkinson's disease across the globe. Additionally, rising awareness about these diseases and their treatment options is also propelling the demand for glucosylceramidase products globally. Based on type, the global glucosylceramidase market can be segmented into AVRRD-02, LTI-291, NCGC-607, Pcgin and others. Among these types, AVRRD-02 held a dominant share in 2017 and is expected to maintain its lead during the forecast period as well. This can be attributed to its high efficacy in treating various genetic disorders such as Gaucher disease and Fabry disease. Based on application, the global glucosylceramidase market can be segmented into genetic disorders (Gaucher Disease), Parkinson's Disease) and others (Fabry Disease).
Product Definition:
A glycoprotein enzyme that catalyzes the hydrolysis of glucosylceramide to ceramide and glucose. Glucosylceramidase is important for the degradation of lipids within cells.
AVRRD-02:
AVRRD-02 is a novel small molecule that has been shown to be effective in the treatment of patients with Becker's syndrome and multiple myeloma. The AVRRD-02 clinical trial was completed in 2015, with results showing positive primary and secondary endpoint data. Since then, the compound has undergone extensive further development work including oral administration to enable its use as a first line treatment for these diseases; this work was published in 2016.
LTI-291:
LTI- 291 is a novel, Potent and selective inhibitor of glucosylceramidase. It has been discovered by characterizing an L-glucosaminyl transferase from Aspergillus oryzae. The enzyme catalyses the hydrolysis of N-glycans to form D - mannose and L - glucose.
Application Insights:
The genetic disorders segment dominated the global glucosylceramidase market in terms of revenue share in 2017. The application is driven by a high prevalence of genetic diseases that require enzyme replacement therapy, which is not available commercially. Genetic disorders include Hunter¢â‚¬â„¢s syndrome, cystic fibrosis, hemoglobin C disease, and others.
Glucosylceramide (GlcCer) plays an important role in the treatment of several rare diseases including Gaucher disease and Parkinson's disease as it helps maintain cell membranes stability and function properly. Therefore, increasing awareness regarding these applications will drive product demand over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing awareness levels are some of the factors responsible for its continued dominance. For instance, in August 2016, BioMarin Pharmaceuticals received approval from the U.S FDA for SGLCT-targeted drug Zynteglo (formerly Zytiga).
Asia Pacific is expected to be one of fastest growing regions over the forecast period owing to various initiatives taken by government bodies and research organizations to increase R&D activities related to rare diseases & personalized medicine in this region. In September 2015; GlaxoSmithKline (GSK) invested around USD X million towards research on glucosylceramidease deficiency at University Of Cambridge Institute For Medical Research Ltd.
Growth Factors:
- Increasing prevalence of Gaucher disease: The global prevalence of Gaucher disease is estimated to be around 1 in 40,000-60,000 individuals. This number is expected to increase due to the increasing awareness about the disease and advancements in diagnosis and treatment options.
- Growing demand for enzyme replacement therapy: The market for enzyme replacement therapy is growing rapidly due to the high efficacy and safety profile of these therapies. Glucosylceramidase is one of the key enzymes involved in this therapy, which is expected to drive the growth of the glucosylceramidase market over the next few years.
- Rising R&D investments by pharmaceutical companies: Pharmaceutical companies are investing heavily in R&D activities aimed at developing novel therapies for Gaucher disease and other lysosomal storage disorders (LSDs). This is likely to result in increased availability of glucosylceramidase products over the next few years, driving market growth.
- Growing number of clinical trials: A large number of clinical trials are being conducted globally on various glucosylceramidase products with a view to assess their safety and efficacy profiles across different patient populations. This will help expand product indications over time, fueling market growth further.
Scope Of The Report
Report Attributes
Report Details
Report Title
Glucosylceramidase Market Research Report
By Type
AVRRD-02, LTI-291, NCGC-607, Pcgin, Others
By Application
Genetic Disorders, Gaucher Disease, Parkinson's Disease, Others
By Companies
Amicus Therapeutics, Inc., Bioorganic Research and Services S.A., greenovation Biotech GmbH, JCR Pharmaceuticals Co., Ltd., Pharming Group N.V., Protalix BioTherapeutics, Inc., Shire Plc, The International Biotechnology Center (IBC) Generium
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Glucosylceramidase Market Report Segments:
The global Glucosylceramidase market is segmented on the basis of:
Types
AVRRD-02, LTI-291, NCGC-607, Pcgin, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Genetic Disorders, Gaucher Disease, Parkinson's Disease, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amicus Therapeutics, Inc.
- Bioorganic Research and Services S.A.
- greenovation Biotech GmbH
- JCR Pharmaceuticals Co., Ltd.
- Pharming Group N.V.
- Protalix BioTherapeutics, Inc.
- Shire Plc
- The International Biotechnology Center (IBC) Generium
Highlights of The Glucosylceramidase Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- AVRRD-02
- LTI-291
- NCGC-607
- Pcgin
- Others
- By Application:
- Genetic Disorders
- Gaucher Disease
- Parkinson's Disease
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Glucosylceramidase Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Glucosylceramidase is an enzyme that breaks down glucosylceramide. Glucosylceramide is a type of glycoprotein found in the cell walls of some plants and animals.
Some of the major players in the glucosylceramidase market are Amicus Therapeutics, Inc., Bioorganic Research and Services S.A., greenovation Biotech GmbH, JCR Pharmaceuticals Co., Ltd., Pharming Group N.V., Protalix BioTherapeutics, Inc., Shire Plc, The International Biotechnology Center (IBC) Generium.
The glucosylceramidase market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Glucosylceramidase Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Glucosylceramidase Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Glucosylceramidase Market - Supply Chain
4.5. Global Glucosylceramidase Market Forecast
4.5.1. Glucosylceramidase Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Glucosylceramidase Market Size (000 Units) and Y-o-Y Growth
4.5.3. Glucosylceramidase Market Absolute $ Opportunity
5. Global Glucosylceramidase Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Glucosylceramidase Market Size and Volume Forecast by Type
5.3.1. AVRRD-02
5.3.2. LTI-291
5.3.3. NCGC-607
5.3.4. Pcgin
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Glucosylceramidase Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Glucosylceramidase Market Size and Volume Forecast by Application
6.3.1. Genetic Disorders
6.3.2. Gaucher Disease
6.3.3. Parkinson's Disease
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Glucosylceramidase Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Glucosylceramidase Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Glucosylceramidase Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Glucosylceramidase Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Glucosylceramidase Demand Share Forecast, 2019-2026
9. North America Glucosylceramidase Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Glucosylceramidase Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Glucosylceramidase Market Size and Volume Forecast by Application
9.4.1. Genetic Disorders
9.4.2. Gaucher Disease
9.4.3. Parkinson's Disease
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Glucosylceramidase Market Size and Volume Forecast by Type
9.7.1. AVRRD-02
9.7.2. LTI-291
9.7.3. NCGC-607
9.7.4. Pcgin
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Glucosylceramidase Demand Share Forecast, 2019-2026
10. Latin America Glucosylceramidase Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Glucosylceramidase Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Glucosylceramidase Market Size and Volume Forecast by Application
10.4.1. Genetic Disorders
10.4.2. Gaucher Disease
10.4.3. Parkinson's Disease
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Glucosylceramidase Market Size and Volume Forecast by Type
10.7.1. AVRRD-02
10.7.2. LTI-291
10.7.3. NCGC-607
10.7.4. Pcgin
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Glucosylceramidase Demand Share Forecast, 2019-2026
11. Europe Glucosylceramidase Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Glucosylceramidase Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Glucosylceramidase Market Size and Volume Forecast by Application
11.4.1. Genetic Disorders
11.4.2. Gaucher Disease
11.4.3. Parkinson's Disease
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Glucosylceramidase Market Size and Volume Forecast by Type
11.7.1. AVRRD-02
11.7.2. LTI-291
11.7.3. NCGC-607
11.7.4. Pcgin
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
1110. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Glucosylceramidase Demand Share, 2019-2026
12. Asia Pacific Glucosylceramidase Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Glucosylceramidase Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Glucosylceramidase Market Size and Volume Forecast by Application
12.4.1. Genetic Disorders
12.4.2. Gaucher Disease
12.4.3. Parkinson's Disease
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Glucosylceramidase Market Size and Volume Forecast by Type
12.7.1. AVRRD-02
12.7.2. LTI-291
12.7.3. NCGC-607
12.7.4. Pcgin
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Glucosylceramidase Demand Share, 2019-2026
13. Middle East & Africa Glucosylceramidase Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Glucosylceramidase Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Glucosylceramidase Market Size and Volume Forecast by Application
13.4.1. Genetic Disorders
13.4.2. Gaucher Disease
13.4.3. Parkinson's Disease
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Glucosylceramidase Market Size and Volume Forecast by Type
13.7.1. AVRRD-02
13.7.2. LTI-291
13.7.3. NCGC-607
13.7.4. Pcgin
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Glucosylceramidase Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Glucosylceramidase Market: Market Share Analysis
14.2. Glucosylceramidase Distributors and Customers
14.3. Glucosylceramidase Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Amicus Therapeutics, Inc.
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bioorganic Research and Services S.A.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. greenovation Biotech GmbH
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. JCR Pharmaceuticals Co., Ltd.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Pharming Group N.V.
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Protalix BioTherapeutics, Inc.
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Shire Plc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. The International Biotechnology Center (IBC) Generium
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
